Global Cord Blood Corporation

Equities

CORBF

KYG393421030

Healthcare Facilities & Services

Market Closed - OTC Markets Other stock markets 03:04:15 2024-04-26 pm EDT			5-day change	1st Jan Change
1.25 ^USD	0.00%		0.00%	+2.46%

2023	Global Cord Blood Corporation Announces Board Appointments	CI
2023	Global Cord Blood Corporation(NYSE:CO) dropped from S&P Global BMI Index	CI

Global Cord Blood Shares Rise 15% After Merger Target Gets FDA Clearance for IND

June 17, 2022 at 12:35 pm EDT

By Chris Wack

Global Cord Blood Corp. shares were up 15% to $3.42 after the company said Cellenkos Inc. recently got U.S. Food and Drug Administration clearance for its Investigational New Drug application for CK0804.

This clearance allows Cellenkos to initiate a Phase 1b, open-label study of CK0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.

Global Cord Blood agreed to buy biotechnology company Cellenkos in April. At closing, Global Cord will issue 125 million new shares valued at $11 a share, and pay $664 million in cash.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

06-17-22 1234ET

Latest news about Global Cord Blood Corporation

Global Cord Blood Corporation Announces Board Appointments	23-09-29	CI
Global Cord Blood Corporation(NYSE:CO) dropped from S&P Global BMI Index	23-03-20	CI
Global Cord Blood Corporation Announces Board Changes	23-02-17	CI
China Cord Blood Posts Lower Fiscal Q4 Profit, Revenue	22-07-06	MT
Global Cord Blood Corporation Reports Earnings Results for the Full Year Ended March 31, 2022	22-07-05	CI
Earnings Flash (CO) GLOBAL CORD BLOOD CORPORATION Posts Q4 EPS $0.14	22-07-05	MT
Global Cord Blood Corporation Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-07-05	CI
Global Cord Blood Shares Rise 15% After Merger Target Gets FDA Clearance for IND	22-06-17	DJ
Global Cord Says Cellenkos Gets US FDA OK of IND Application for CK0804 as Add-on Therapy to Ruxolitinib for Myelofibrosis	22-06-16	MT
Global Cord Blood Corporation Approves Board Changes	22-06-16	CI
Global Cord Blood Shareholder Blue Ocean Says EGM Called to Vote on Cellenkos Deal Cancelation Proposal	22-06-03	MT
Global Cord Blood Corporation Proposes Board Changes	22-06-03	CI
Global Cord Blood Corporation (NYSE:CO) cancelled the acquisition of an unknown stake in Cellenkos, Inc. from Leong Kim Chuan.	22-05-19	CI
Blue Ocean Structure Provides Information to Shareholders of Global Cord	22-05-13	CI
Blue Ocean Structure Investment Company Limited Communicates with Global Cord Blood Corporation	22-05-13	CI
Blue Ocean Structure Investment Company Limited Sues Global Cord Blood Corporation	22-05-09	CI
China Cord Blood's Stock Down 35%; Announces Acquisition of Cellenkos	22-05-02	MT
Global Cord Blood Corporation (NYSE : CO) entered into an agreement to acquire an unknown stake in Cellenkos, Inc. from Leong Kim Chuan.	22-04-28	CI
Transcript : Global Cord Blood Corporation, Q3 2022 Earnings Call, Mar 01, 2022	22-03-01
Global Cord Blood Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-28	CI
Health Care Stocks Point Lower Premarket Friday	21-12-17	MT
Global Cord Blood Rejects Takeover Bid From Alternate Ocean Investment	21-12-16	MT
Unknown buyers cancelled the acquisition of Global Cord Blood Corporation (NYSE:CO) from Blue Ocean Structure Investment Company Ltd. and others.	21-12-15	CI
Transcript : Global Cord Blood Corporation, Q2 2022 Earnings Call, Nov 26, 2021	21-11-26
Global Cord Blood Corporation Posts Lower Q2 Profit Amid Higher Revenue -- Stock Up 2% After-Hours	21-11-24	MT

Chart Global Cord Blood Corporation

Duration

Period

More charts

Company Profile

Global Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People's Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. It also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. The Company provides cord blood processing and storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies, such as cord blood transplants. It also preserves cord blood units donated by the public; provides matching services on such donated units, and delivers matching units to patients in need of transplants.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
GLOBAL CORD BLOOD CORPORATION	+2.46%	167M
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.62%	29.59B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-2.49%	16.36B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
PURE HEALTH HOLDING	-31.58%	11.77B
FRESENIUS MEDICAL CARE AG	-0.50%	11.72B
DAVITA INC.	+27.44%	11.71B

Other Healthcare Facilities & Services